FI20050011A0 - Menetelmä ja testipakkaus tyypin 2 diabetes mellituksen riskin havaitsemiseksi - Google Patents
Menetelmä ja testipakkaus tyypin 2 diabetes mellituksen riskin havaitsemiseksiInfo
- Publication number
- FI20050011A0 FI20050011A0 FI20050011A FI20050011A FI20050011A0 FI 20050011 A0 FI20050011 A0 FI 20050011A0 FI 20050011 A FI20050011 A FI 20050011A FI 20050011 A FI20050011 A FI 20050011A FI 20050011 A0 FI20050011 A0 FI 20050011A0
- Authority
- FI
- Finland
- Prior art keywords
- risk
- detect
- procedure
- type
- diabetes mellitus
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/172—Haplotypes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/04—Endocrine or metabolic disorders
- G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
- Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Analytical Chemistry (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Pathology (AREA)
- Genetics & Genomics (AREA)
- General Physics & Mathematics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Food Science & Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- General Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Cell Biology (AREA)
- Biophysics (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FI20050011A FI20050011A (fi) | 2005-01-05 | 2005-01-05 | Menetelmä ja testipakkaus tyypin 2 diabetes mellituksen riskin havaitsemiseksi |
CA002593473A CA2593473A1 (en) | 2005-01-05 | 2005-12-23 | Novel genes and markers associated to type 2 diabetes mellitus |
JP2007549923A JP2008527977A (ja) | 2005-01-05 | 2005-12-23 | 2型糖尿病に関連する新規遺伝子とマーカー |
PCT/FI2005/050486 WO2006072654A1 (en) | 2005-01-05 | 2005-12-23 | Novel genes and markers associated to type 2 diabetes mellitus |
EP05820627.7A EP1833988B1 (en) | 2005-01-05 | 2005-12-23 | Novel genes and markers associated to type 2 diabetes mellitus |
US11/325,330 US20070059722A1 (en) | 2005-01-05 | 2006-01-05 | Novel genes and markers associated to type 2 diabetes mellitus |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FI20050011A FI20050011A (fi) | 2005-01-05 | 2005-01-05 | Menetelmä ja testipakkaus tyypin 2 diabetes mellituksen riskin havaitsemiseksi |
Publications (2)
Publication Number | Publication Date |
---|---|
FI20050011A0 true FI20050011A0 (fi) | 2005-01-05 |
FI20050011A FI20050011A (fi) | 2006-07-06 |
Family
ID=34112546
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FI20050011A FI20050011A (fi) | 2005-01-05 | 2005-01-05 | Menetelmä ja testipakkaus tyypin 2 diabetes mellituksen riskin havaitsemiseksi |
Country Status (6)
Country | Link |
---|---|
US (1) | US20070059722A1 (fi) |
EP (1) | EP1833988B1 (fi) |
JP (1) | JP2008527977A (fi) |
CA (1) | CA2593473A1 (fi) |
FI (1) | FI20050011A (fi) |
WO (1) | WO2006072654A1 (fi) |
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8119358B2 (en) | 2005-10-11 | 2012-02-21 | Tethys Bioscience, Inc. | Diabetes-related biomarkers and methods of use thereof |
WO2008003826A1 (en) * | 2006-07-07 | 2008-01-10 | Oy Jurilab Ltd | Novel genes and markers in essential arterial hypertension |
JP2008023199A (ja) * | 2006-07-24 | 2008-02-07 | Katsuzo Kawanishi | メタボリックシンドローム診断装置、メタボリックシンドローム診断プログラム、体組成計、及び血圧計 |
US7951776B2 (en) * | 2006-09-01 | 2011-05-31 | American Type Culture Collection | Methods for treatment of type 1 diabetes |
US20100267052A1 (en) * | 2006-09-01 | 2010-10-21 | American Type Culture Collection | Compositions and methods for diagnosis and treatment of type 2 diabetes |
US20090203602A1 (en) * | 2006-09-01 | 2009-08-13 | Cohava Gelber | Compositions and methods for diagnosis and treatment of type 2 diabetes |
US20080300170A1 (en) * | 2006-09-01 | 2008-12-04 | Cohava Gelber | Compositions and methods for diagnosis and treatment for type 2 diabetes |
KR100818276B1 (ko) * | 2006-09-27 | 2008-03-31 | 삼성전자주식회사 | 알콜 분해 능력과 숙취 발생 여부를 예측하기 위한프라이머 세트, 프로브 세트, 방법 및 키트 |
DE102006052916A1 (de) * | 2006-11-08 | 2008-05-15 | Brahms Aktiengesellschaft | Diagnose und Risikostratifizierung von Diabetes mellitus mittels MR-proADM |
TW200849035A (en) * | 2007-04-18 | 2008-12-16 | Tethys Bioscience Inc | Diabetes-related biomarkers and methods of use thereof |
JP5433189B2 (ja) * | 2007-09-28 | 2014-03-05 | 承一 尾崎 | Mpo−anca関連血管炎の被験者に対する治療の効果を予測する材料を提供する方法 |
US20100311092A1 (en) * | 2007-11-30 | 2010-12-09 | Kurland Irwin J | Metabolic fuel switching biomarker |
US9817001B2 (en) | 2008-05-27 | 2017-11-14 | Boston Heart Diagnostics Corporation | Methods for determining LDL cholesterol treatment |
US8470541B1 (en) | 2008-09-27 | 2013-06-25 | Boston Heart Diagnostics Corporation | Methods for separation and immuno-detection of biomolecules, and apparatus related thereto |
WO2010072608A1 (en) * | 2008-12-22 | 2010-07-01 | F. Hoffmann-La Roche Ag | Pcsk1 single nucleotide polymorphism in type 2 diabetes |
EP2494364A1 (en) * | 2009-10-29 | 2012-09-05 | Tethys Bioscience, Inc. | Protein and lipid biomarkers providing consistent improvement to the prediction of type 2 diabetes |
ES2818138T3 (es) | 2009-12-20 | 2021-04-09 | Astute Medical Inc | Métodos y composiciones para el diagnóstico y pronóstico de lesión renal e insuficiencia renal |
NZ602056A (en) * | 2010-02-26 | 2014-11-28 | Astute Medical Inc | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
US20120094279A1 (en) * | 2010-07-19 | 2012-04-19 | Jiwu Wang | Use of enzymes for altering ratios of partially matched polynucleotides |
WO2012038827A2 (en) * | 2010-09-20 | 2012-03-29 | Prognomix Inc. | Genes linking several complications of type-2 diabetes (t2d) |
EP2652149A2 (en) * | 2010-12-16 | 2013-10-23 | Norwegian University of Science and Technology (NTNU) | Single nucleotide polymorphism associated with risk of insulin resistance development |
CN102854325B (zh) * | 2011-07-01 | 2015-01-07 | 复旦大学 | 胰岛素与血清蛋白可逆性结合的亲和力指标测定方法及应用 |
US8765377B2 (en) | 2011-10-13 | 2014-07-01 | Boston Heart Diagnostics Corporation | Compositions and methods for treating and preventing coronary heart disease |
EP2788759B1 (en) | 2011-12-08 | 2019-02-20 | Astute Medical, Inc. | Methods and uses for diagnosis of renal injury and renal failure |
US10242756B2 (en) | 2012-09-21 | 2019-03-26 | Ethicon Endo-Surgery, Inc. | Systems and methods for predicting metabolic and bariatric surgery outcomes |
EP2898101A4 (en) | 2012-09-21 | 2016-08-03 | Ethicon Endo Surgery Inc | CLINICAL PREDICTORS FOR WEIGHT LOSS |
WO2014047388A1 (en) | 2012-09-21 | 2014-03-27 | Ethicon Endo-Surgery, Inc. | Systems and methods for predicting metabolic and bariatric surgery outcomes |
US20140120559A1 (en) * | 2012-10-26 | 2014-05-01 | Boston Heart Diagnostics Corporation | Diabetes panel |
CN105074466B (zh) | 2013-01-17 | 2018-01-09 | 阿斯图特医药公司 | 用于肾损伤和肾衰竭的诊断及预后的方法和组合物 |
US9828624B2 (en) | 2013-07-24 | 2017-11-28 | Boston Heart Diagnostics Corporation | Driving patient compliance with therapy |
CA2968221A1 (en) | 2014-11-17 | 2016-05-26 | Boston Heart Diagnostic Corporation | Cardiovascular disease risk assessment |
CN109844526A (zh) | 2016-06-06 | 2019-06-04 | 机敏医药股份有限公司 | 使用胰岛素样生长因子结合蛋白7和金属蛋白酶2的组织抑制剂管理急性肾损伤 |
HRP20160662A2 (hr) | 2016-06-13 | 2017-12-15 | Genos D.O.O. | Postupak predviđanja razvoja dijabetesa tipa 2 putem analize n-glikana iz krvne plazme zdravih osoba |
CN107256323B (zh) * | 2016-09-05 | 2020-11-13 | 云健康基因科技(上海)有限公司 | 一种ⅱ型糖尿病风险评估模型的构建方法和构建系统 |
CN112513295A (zh) * | 2018-06-15 | 2021-03-16 | Opti 西拉公司 | 用于预测疾病并发症和/或对治疗的反应的多基因风险评分 |
JP7096784B2 (ja) * | 2019-04-23 | 2022-07-06 | ジェネシスヘルスケア株式会社 | 妊娠糖尿病のリスクを判定する方法 |
US20210272661A1 (en) * | 2020-02-27 | 2021-09-02 | The Cleveland Clinic Foundation | Identifying patients for intensive hyperglycemia management |
KR102304399B1 (ko) * | 2021-03-26 | 2021-09-24 | 주식회사 에이치이엠파마 | 머신러닝 모델을 이용하여 고혈당을 판별하는 방법 및 진단 장치 |
CN117219158A (zh) * | 2022-12-02 | 2023-12-12 | 上海爱谱蒂康生物科技有限公司 | 一种肠癌个性化治疗决策方法、系统及含其的存储介质 |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030204075A9 (en) * | 1999-08-09 | 2003-10-30 | The Snp Consortium | Identification and mapping of single nucleotide polymorphisms in the human genome |
WO2001057190A2 (en) * | 2000-02-03 | 2001-08-09 | Hyseq, Inc. | Novel nucleic acids and polypeptides |
AU2001241735A1 (en) * | 2000-02-25 | 2001-09-03 | Pharmacia And Upjohn Company | Novel g protein-coupled receptors |
US6812339B1 (en) * | 2000-09-08 | 2004-11-02 | Applera Corporation | Polymorphisms in known genes associated with human disease, methods of detection and uses thereof |
US20030092019A1 (en) * | 2001-01-09 | 2003-05-15 | Millennium Pharmaceuticals, Inc. | Methods and compositions for diagnosing and treating neuropsychiatric disorders such as schizophrenia |
AU2003210518A1 (en) * | 2002-01-16 | 2003-09-02 | Incyte Genomics, Inc. | Molecules for diagnostics and therapeutics |
AU2003298556A1 (en) * | 2002-08-19 | 2004-05-04 | Regulome Corporation | Functional sites |
US7300788B2 (en) * | 2002-10-08 | 2007-11-27 | Affymetrix, Inc. | Method for genotyping polymorphisms in humans |
FI117516B (fi) * | 2002-12-11 | 2006-11-15 | Jurilab Ltd Oy | Menetelmä ja reagenssipakkaus diabetesriskin havainnoimiseksi |
WO2004067771A1 (en) * | 2003-01-30 | 2004-08-12 | Hvidovre Hospital | Association of the gys1 genotype with increased risk for diabetes mellitus type 2 |
EP1449925A1 (en) * | 2003-02-20 | 2004-08-25 | Centre National De La Recherche Scientifique (Cnrs) | Method of diagnosis of type 2 diabetes |
JPWO2004084797A1 (ja) * | 2003-02-28 | 2006-06-29 | ヒュ—ビット ジェノミクス株式会社 | 2型糖尿病関連遺伝子、およびその利用 |
US20070203083A1 (en) * | 2003-06-13 | 2007-08-30 | Mootha Vamsi K | Methods Of Regulating Metabolism And Mitochondrial Function |
JP4488697B2 (ja) * | 2003-07-01 | 2010-06-23 | タマティーエルオー株式会社 | 組立型風車 |
JP2005198640A (ja) * | 2003-11-25 | 2005-07-28 | Biomarker Science:Kk | 遺伝子発現方法 |
WO2006010514A2 (en) * | 2004-07-29 | 2006-02-02 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with dual specificity mitogen-activated protein kinase kinase 5 (map2k5) |
-
2005
- 2005-01-05 FI FI20050011A patent/FI20050011A/fi not_active Application Discontinuation
- 2005-12-23 JP JP2007549923A patent/JP2008527977A/ja not_active Withdrawn
- 2005-12-23 CA CA002593473A patent/CA2593473A1/en not_active Abandoned
- 2005-12-23 WO PCT/FI2005/050486 patent/WO2006072654A1/en active Application Filing
- 2005-12-23 EP EP05820627.7A patent/EP1833988B1/en not_active Not-in-force
-
2006
- 2006-01-05 US US11/325,330 patent/US20070059722A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP1833988B1 (en) | 2013-08-14 |
EP1833988A1 (en) | 2007-09-19 |
EP1833988A4 (en) | 2009-11-11 |
US20070059722A1 (en) | 2007-03-15 |
WO2006072654A1 (en) | 2006-07-13 |
FI20050011A (fi) | 2006-07-06 |
CA2593473A1 (en) | 2006-07-13 |
JP2008527977A (ja) | 2008-07-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FI20050011A0 (fi) | Menetelmä ja testipakkaus tyypin 2 diabetes mellituksen riskin havaitsemiseksi | |
ATE475706T1 (de) | Abgeschwächter dengue-serotyp-2-stamm | |
ATE483984T1 (de) | Messung der thrombinaktivität in vollblut | |
DE602007013939D1 (de) | Pestizidzusammensetzung mit fenamidon und insektizidverbindung | |
DE602006009656D1 (de) | 1-ä(3-hydroxy-adamant-1-ylamino)-acetylü-pyrrolidin-2(s)-carbonitril-formulierung mit modifizierter freisetzung | |
EP1883816A4 (en) | DIAGNOSTIC DEVICE FOR MEASURING THE RELATIONSHIP OF PROTEINS WITH SIMILAR STRUCTURE | |
DE602006018166D1 (de) | Polyrotaxanhaltige lösung und verwendung davon | |
DE602006003000D1 (de) | Polarimeter zur gleichzeitigen Messung der Stokes-Parameter von Licht | |
FI20041340A0 (fi) | Menetelmä ja testipakkaus äkillisen sydäninfarktin riskin havaitsemiseksi | |
DE602005024107D1 (de) | Flüssigkristall wiedergabeanordnung | |
FI20050809A0 (fi) | Värikoostumus, happi- ja/tai pH-indikaattori ja pakkaus | |
DK1768380T3 (da) | Farvedensitetsmåleapparatur | |
FR2883154B1 (fr) | Dispositif de mesure du teint | |
FI20041490A0 (fi) | Menetelmä ja testipakkaus olennaisesti kohonneen verenpaineen riskin havaitsemiseksi | |
DE602006018617D1 (de) | Pharmazeutische zusammensetzung mit 2,3-dihydro-6-nitroimidazoä2,1-büoxazolderivaten | |
FI20022178A0 (fi) | Menetelmä ja testipakkaus diabetesriskin havaitsemiseksi | |
FI20055231A (fi) | Menetelmä ja mittalaite mitata vesipitoisuutta | |
ITMI20051913A1 (it) | Liposomi caricati con fullerene e procediento per la loro preparazione | |
DE502005001053D1 (de) | Massverkörperung mit parallelen Massbändern | |
FI20060396A0 (fi) | Tasopinta ja siihen integroitu pinta kuten näyttöpinta | |
BRPI0811940A2 (pt) | Composição inseticida e os artigos obtidos da mesma | |
NO20070846L (no) | Gjennomtrengelig forpakningsmateriale | |
FI20051009A (fi) | Mittausmenetelmä, järjestely ja ohjelmistotuote | |
BRPI0822068A2 (pt) | Derivado de 17-(-1'-propenil)-17-3'-oxidoestra-4-en-3-ona, seu uso e o medicamento contendo o derivado | |
DE602006009716D1 (de) | Grundumsatzmesseinrichtung |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FD | Application lapsed |